Gossamer Bio (NASDAQ:GOSS) Stock Rating Lowered by Wall Street Zen

Gossamer Bio (NASDAQ:GOSS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.

GOSS has been the topic of a number of other reports. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $11.28 on Friday. Gossamer Bio has a 1 year low of $9.10 and a 1 year high of $309.60. The stock’s fifty day moving average price is $13.11 and its two-hundred day moving average price is $20.19. The company has a market cap of $33.05 million, a P/E ratio of -0.20 and a beta of 2.00.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently modified their holdings of GOSS. Eaton Financial Holdings Company LLC purchased a new position in shares of Gossamer Bio during the fourth quarter worth about $44,000. Caitong International Asset Management Co. Ltd raised its stake in Gossamer Bio by 22.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after purchasing an additional 4,771 shares in the last quarter. ProShare Advisors LLC lifted its position in Gossamer Bio by 39.6% during the fourth quarter. ProShare Advisors LLC now owns 45,338 shares of the company’s stock valued at $141,000 after purchasing an additional 12,863 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock valued at $189,000 after purchasing an additional 50,666 shares during the last quarter. Finally, AXQ Capital LP grew its stake in Gossamer Bio by 36.1% in the 4th quarter. AXQ Capital LP now owns 63,117 shares of the company’s stock worth $196,000 after buying an additional 16,750 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.